ArticleMolecular cancer therapeutics2023

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER.

Jeff Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.